PCSK9 Inhibitors Explained: All 5 Options

What is a PCSK9 inhibitor?

A PCSK9 inhibitor is a cholesterol medicine that helps your liver pull more LDL out of your blood, lowering LDL by about 50 to 60% on top of a statin. It works by blocking (or reducing) PCSK9, a liver protein that breaks down LDL receptors.

LDL receptors are the docking stations that pull LDL cholesterol out of your bloodstream. More PCSK9 means fewer receptors, which means more LDL circulating. Block PCSK9 and your liver keeps more receptors active, so more LDL gets cleared. PCSK9 inhibitors rank among the most powerful LDL-lowering options available.

Which PCSK9 inhibitors are available?

Five PCSK9 inhibitors are available in the US as of October 2026: Repatha, Praluent, Leqvio, Lipfendra and Lerochol. They're one class delivered in different ways:

• Evolocumab (Repatha): a self-injection, every two weeks or monthly, using a monoclonal antibody that directly blocks PCSK9
• Alirocumab (Praluent): the same antibody approach, self-injected every two or four weeks
• Inclisiran (Leqvio): an siRNA therapy given by a healthcare professional, twice a year after the first two doses, that stops the liver from making PCSK9 in the first place rather than blocking it after the fact. See our Leqvio guide
• Enlicitide (Lipfendra): the first oral PCSK9 inhibitor, FDA-approved in July 2026, taken once daily. See our Lipfendra guide
• Lerodalcibep (Lerochol): a third-generation PCSK9 inhibitor, available in the US since May 2026, self-injected once a month instead of every two weeks. See our dedicated Lerochol guide for details

Do PCSK9 inhibitors prevent heart attacks?

Yes, for the two with completed outcomes trials. Repatha and Praluent both lowered the risk of heart attacks and strokes in those trials, on top of lowering LDL numbers.

The largest trial in the class, FOURIER, followed over 27,000 patients with established cardiovascular disease already on a statin. Adding evolocumab lowered LDL-C by 59%, from a median of 92 to 30 mg/dL, and reduced the combined risk of cardiovascular death, heart attack, stroke, hospitalization for unstable angina, or a procedure to open an artery by 15%.

Imaging data from the GLAGOV trial went further. Adding evolocumab to a statin shrank plaque inside the coronary arteries, with regression in 64% of patients on evolocumab compared with 47% on placebo.

Leqvio, Lipfendra and Lerochol are approved based on how much they lower LDL. Their outcomes trials haven't reported yet.

Do PCSK9 inhibitors lower Lp(a)?

Yes, by about a quarter. In FOURIER, evolocumab lowered Lp(a) by a median of 27%, and people with higher Lp(a) tended to get more coronary benefit from treatment.

Lp(a) lowering remains a side benefit outside the approved uses. No medicine is yet FDA-approved specifically to lower Lp(a). The 2026 ACC/AHA multisociety guideline recommends measuring Lp(a) at least once in every adult (JACC), and our advanced lipid testing page explains how to get it checked.

Side effects and downsides of PCSK9 inhibitors

Side effects are usually mild. With the injectables, the most common are injection-site reactions (redness, pain or bruising where the shot goes in) and cold-like symptoms.

The trial data:

• Repatha: in FOURIER, the only adverse event more common than with placebo was injection-site reactions (2.1% vs 1.6%). There was no increase in new-onset diabetes or neurocognitive events.
• Memory: the EBBINGHAUS substudy tested memory and thinking directly in 1,204 FOURIER patients over a median of 19 months and found no difference from placebo.
• Lerochol: the most common side effects in its trials were nasopharyngitis (a cold), injection-site reactions and peripheral swelling (LIB Therapeutics).
• Lipfendra: in people with familial hypercholesterolemia, diarrhea and dizziness were slightly more common than with placebo (prescribing information).

The practical downsides tend to matter more than the medical ones: cost, insurance paperwork, the injection itself for most options, and, for the three newest drugs, outcomes evidence that's still coming.

Is a PCSK9 inhibitor a statin?

No. Statins slow the liver's production of cholesterol, while PCSK9 inhibitors help the liver remove more LDL from the blood. They're different classes that add together, and a PCSK9 inhibitor can be used with or without a statin.

People with confirmed statin intolerance are one of the main groups who take a PCSK9 inhibitor on its own, so trouble with statins doesn't rule one out.

Who qualifies for a PCSK9 inhibitor?

PCSK9 inhibitors are typically considered for people whose LDL or ApoB is still above target on the statin they can tolerate, people who can't take statins, and people with familial hypercholesterolemia. More specifically, people who:

• Have LDL-C or ApoB still above target despite a maximum-tolerated statin, with or without ezetimibe
• Cannot tolerate statins at any meaningful dose
• Have familial hypercholesterolemia
• Have established cardiovascular disease and persistently elevated LDL-C

The 2026 ACC/AHA multisociety dyslipidemia guideline sets an LDL-C goal under 70 mg/dL for people with cardiovascular disease and under 55 mg/dL for those at very high risk. When LDL stays above goal on a statin, it says adding ezetimibe and/or a PCSK9 inhibitor "should be implemented without delay" (ACC).

Why is a PCSK9 inhibitor hard to get covered?

Mostly because of step therapy and prior authorization. Many insurers want documented trials of a statin, and often ezetimibe, before they'll pay for a PCSK9 inhibitor, even for patients who clearly meet the clinical criteria.

Each plan writes its own criteria, and plan policies don't always match the newest guideline right away. A request that includes the diagnosis, a recent lipid panel, and the exact statins, doses and dates you tried is far easier for a plan to approve than one that leaves gaps.

How do you get a PCSK9 inhibitor?

You can get one through insurance with prior authorization, or by paying cash through a manufacturer's direct program.

1. Through insurance, which usually means a documented statin and ezetimibe history and a prior authorization
2. Cash pay, where the medication is bought directly without waiting on insurance approval. Repatha is $239 a month through AmgenNow and Lerochol is $199 a month through LIB Therapeutics, as of October 2026 (see what Repatha actually costs and our cash-pay pathway)

Preval Health runs as a cash practice. Licensed clinicians in our partner network prescribe PCSK9 inhibitors through direct cash programs, including the oral Lipfendra and the monthly Lerochol, so you skip the prior authorization wait. If your insurer denied one, you can start here. See how to get a PCSK9 inhibitor prescription.

Summary

PCSK9 inhibitors are some of the most effective cholesterol medications available, backed by large outcomes trials, and now available as a daily pill or a monthly shot as well as the original injections. For most people, the paperwork takes more effort than the medicine.